Candida II + Candidiasis

Dr Harish M Nair

Sep 28

16 min read

Clinical syndromes → laboratory diagnosis → interpretation → Candida auris

This is where Candida stops being a morphology chapter and becomes clinical microbiology.

The central question is no longer simply “Which Candida?” but:

Is Candida colonizing this patient, causing mucosal disease, or causing invasive infection—and does the laboratory result actually prove the syndrome?

For current practice, I’ll integrate the standard IDSA framework with current CDC and Indian ICMR/NCDC information.

1. The Candida clinical spectrum

Think of Candida disease as a continuum:

NORMAL COLONIZATION
       ↓
MUCOSAL DISEASE
       ↓
LOCAL INVASIVE DISEASE
       ↓
CANDIDEMIA
       ↓
DISSEMINATION
       ↓
METASTATIC ORGAN INFECTION

Major syndromes:

Oropharyngeal candidiasis
Esophageal candidiasis
Vulvovaginal candidiasis
Candidemia
Candida endocarditis
Candida UTI
Hepatosplenic/chronic disseminated candidiasis
Chronic mucocutaneous candidiasis

2. Oropharyngeal candidiasis

Also called:

Oral thrush

Typical presentation

White/cream plaques
Tongue
Buccal mucosa
Palate
Oropharynx

A classic feature:

Plaques can often be scraped off, leaving an erythematous underlying surface.

Risk factors

Think:

Antibiotics
Corticosteroids, particularly inhaled corticosteroids
Diabetes
HIV/AIDS
Malignancy
Immunosuppression
Dentures
Xerostomia

3. Laboratory diagnosis of oral candidiasis

Usually:

Clinical diagnosis

Laboratory confirmation is often unnecessary in straightforward cases.

If laboratory investigation is needed:

KOH examination
Gram stain
Fungal culture

May demonstrate:

Budding yeast ± pseudohyphae

Important interpretation

Isolation of Candida from the oral cavity alone does not prove infection, because Candida commonly colonizes the mouth.

4. Esophageal candidiasis

This is an important deeper mucosal infection.

Typical presentation

Odynophagia ± dysphagia

Risk factors:

HIV/AIDS
Malignancy
Steroids
Immunosuppression
Diabetes
Antibiotics
Esophageal motility disorders

Diagnosis

Endoscopy may show:

White plaques
Erythematous mucosa
Friability

Samples can demonstrate:

Candida yeast + pseudohyphae/hyphae

Important clinical concept

Oropharyngeal thrush + odynophagia should immediately make you consider:

Esophageal candidiasis

5. Vulvovaginal candidiasis

One of the most common Candida syndromes.

Usually caused by:

Candida albicans

but non-albicans Candida can occur.

Clinical features

Vulval pruritus
Burning
Erythema
Dysuria
Thick vaginal discharge

Classically:

Thick, white, curd-like discharge

but discharge appearance is not sufficiently specific for diagnosis.

6. Laboratory diagnosis of VVC

Specimen:

Vaginal discharge/vaginal swab

Microscopy

KOH wet mount
Gram stain

Look for:

Budding yeast + pseudohyphae

Culture

Useful particularly in:

Recurrent VVC
Complicated VVC
Treatment failure
Suspected non-albicans Candida

Important point

Finding Candida in a vaginal sample does not always equal symptomatic candidiasis.

You must correlate:

Organism + symptoms + signs

7. Recurrent vulvovaginal candidiasis

Think beyond C. albicans.

Possible organisms include:

C. albicans
C. glabrata
Other non-albicans Candida spp.

This matters because:

Non-albicans Candida may have different antifungal susceptibility and may be more difficult to eradicate.

8. Candidemia

Now we enter the major invasive disease category.

Candida in blood = candidemia

This should be treated as clinically significant.

Unlike Candida isolated from:

Sputum
Oropharyngeal swab
Skin
Some urine specimens

a positive blood culture for Candida is highly significant.

9. Who gets candidemia?

Think:

Hospital patient + breached barriers + devices + antibiotics

Risk factors include:

Central venous catheter
ICU admission
Major abdominal surgery
Total parenteral nutrition
Broad-spectrum antibiotics
Neutropenia
Malignancy
Transplantation
Renal replacement therapy
Prolonged hospitalization

10. Blood culture

The traditional cornerstone of diagnosis of invasive candidiasis remains:

Blood culture

CDC describes blood culture as the primary diagnostic method for invasive candidiasis. (CDC)

Blood culture can provide:

Evidence of bloodstream infection
Isolate for species identification
Isolate for antifungal susceptibility testing

11. But blood culture has an important limitation

A negative blood culture:

Does NOT exclude invasive candidiasis.

This is particularly important in:

Deep-seated candidiasis
Localized intra-abdominal infection
Hepatosplenic candidiasis

Therefore:

Culture-positive candidemia is highly important, but culture-negative disease can occur.

12. What happens when the blood culture flags positive?

Suppose:

Blood culture → budding yeast

Your workflow:

Positive blood culture
       ↓
Gram stain
       ↓
Budding yeast
       ↓
Subculture / direct identification
       ↓
Species identification
       ↓
Antifungal susceptibility
       ↓
Clinical correlation
       ↓
Search for metastatic/deep infection when indicated

13. Species identification matters

Do not stop at:

"Candida species."

You need to know whether it is:

C. albicans
C. glabrata
C. tropicalis
C. parapsilosis
C. krusei
C. auris
Another Candida/yeast

because susceptibility patterns and clinical implications differ.

Current CDC guidance emphasizes species identification to guide antifungal treatment. (CDC)

14. Candidemia — major species associations

Species	Important clinical association
C. albicans	Common invasive pathogen
C. glabrata	Older adults, healthcare-associated infection; reduced azole susceptibility can occur
C. tropicalis	Neutropenia/hematological malignancy; invasive disease
C. parapsilosis	Catheters, neonates, TPN, biofilms
C. krusei	Intrinsic fluconazole resistance
C. auris	Healthcare-associated transmission, colonization, multidrug resistance

15. Candida endocarditis

Rare but extremely important.

Think:

Persistent candidemia + cardiac risk factors

Risk factors include:

Prosthetic valves
Previous valve surgery
Intravascular devices
Prolonged candidemia
Immunosuppression
Injection drug use

Clinical clues

Persistent positive blood cultures
Persistent fever
New murmur
Heart failure
Embolic phenomena

IDSA notes that large embolic events can occur with Candida endocarditis. (Infectious Diseases Society of America)

16. Laboratory diagnosis of Candida endocarditis

Blood culture

May demonstrate persistent candidemia.

Echocardiography

Used to identify:

Vegetations
Valve involvement
Prosthetic valve infection

Microbiology

Species identification + susceptibility testing.

17. Candida UTI

This is a classic interpretation trap.

Candida in urine can represent:

1. Colonization

2. True infection

3. A manifestation of disseminated/invasive disease

Therefore:

Candiduria ≠ automatically Candida UTI.

18. Who develops candiduria?

Risk factors include:

Urinary catheter
Antibiotics
Diabetes
Older age
Hospitalization
Urinary tract abnormalities
Immunosuppression

19. Candiduria — laboratory interpretation

Urine culture may show Candida.

But:

Colony count is not enough to reliably distinguish colonization from infection.

Clinical correlation is essential.

Ask:

Symptoms?
Dysuria?
Frequency?
Fever?
Flank pain?
Obstruction?
Catheter?
Recent instrumentation?

20. Candida pyelonephritis

More significant disease may involve the upper urinary tract.

Possible manifestations:

Fever
Flank pain
Dysuria
Hematuria
Fungus balls/obstruction in some cases

This requires proper clinical evaluation rather than simply treating the culture result.

21. Hepatosplenic candidiasis

Also called:

Chronic disseminated candidiasis

Classically occurs in:

Patients with hematological malignancy and prolonged neutropenia

Pathogenesis

Candida enters the bloodstream and seeds:

Liver
Spleen
Sometimes other organs

During neutropenia:

Clinical manifestations can be subtle.

As neutrophils recover:

Inflammatory symptoms may become more apparent.

22. Clinical picture

Typical:

Persistent fever
Abdominal pain
Elevated liver enzymes
Prolonged fever despite antibacterial therapy
Recent neutropenia

Imaging may show:

Multiple hepatic lesions
Splenic lesions

23. Why blood culture can be negative

This is a crucial point.

Hepatosplenic candidiasis can occur without ongoing candidemia detectable in blood.

Therefore:

Negative blood culture does not exclude chronic disseminated candidiasis.

Diagnosis relies on:

Clinical setting
Imaging
Microbiological evidence where obtainable
Response/evolution over time

24. Chronic mucocutaneous candidiasis

This is different from ordinary recurrent thrush.

It represents:

Persistent/recurrent Candida infection of skin, nails and mucous membranes

Often associated with:

Primary immunodeficiency
T-cell/IL-17 pathway defects
Endocrine abnormalities in certain syndromes

Clinical manifestations

Persistent oral candidiasis
Nail candidiasis/onychomycosis
Chronic skin lesions
Genital mucosal involvement

Important distinction

Recurrent oral thrush alone does not automatically mean chronic mucocutaneous candidiasis.

Think of a chronic, persistent mucocutaneous phenotype with an underlying host-defense problem.

25. Laboratory diagnosis — master framework

Test	Main use	Major limitation
Blood culture	Candidemia	Sensitivity imperfect
Germ tube	Rapid presumptive ID of C. albicans/C. dubliniensis	Not species-specific
Chromogenic agar	Presumptive species differentiation	Colour is medium-dependent; confirm important results
MALDI-TOF MS	Rapid species identification	Database quality matters
Automated biochemical systems	Routine yeast ID	Some species can be misidentified
β-D-glucan	Adjunct for invasive fungal infection	Not Candida-specific
Antifungal susceptibility testing	Guides therapy	Interpretation depends on species/method/breakpoints

26. Germ tube — where does it fit now?

Germ tube is:

A rapid presumptive identification test

Especially useful for:

C. albicans / C. dubliniensis

But it is not a test for invasive candidiasis.

It answers:

"What yeast might this be?"

It does not answer:

"Does this patient have invasive candidiasis?"

That distinction is fundamental.

27. Chromogenic media

Chromogenic media allow presumptive differentiation of Candida based on colony colour.

Typical patterns:

Species	Typical colour pattern*
C. albicans	Green
C. tropicalis	Blue/metallic blue
C. krusei	Pink, dry/rough
C. glabrata	Pink/lavender shades
C. auris	Variable

*Exact appearance depends on the manufacturer and formulation.

Why useful?

You can sometimes go from:

Mixed yeast culture → presumptive species differentiation

without waiting for conventional biochemical identification.

28. MALDI-TOF MS

This has transformed clinical yeast identification.

Principle

The organism generates a characteristic:

Protein spectral fingerprint

The fingerprint is compared with a reference database.

Advantages

Rapid
Species-level identification
Excellent for many yeasts
Useful when colony morphology is non-specific

Limitation

Database quality matters.

This is especially important for:

Candida auris

because older databases/platform versions may not recognize it reliably.

29. Automated systems

Examples include systems based on:

Biochemical assimilation
Chromogenic reactions
Growth characteristics

Examples encountered in clinical microbiology include:

VITEK
BD Phoenix
MicroScan
API systems

They are extremely useful—but:

An automated identification is only as good as the organism database and system version.

This becomes critical with C. auris. CDC specifically notes that traditional systems have misidentified C. auris, and recommends appropriate updated identification methods. (CDC)

30. β-D-glucan

Now the important biomarker.

Fungal cell walls contain:

β-D-glucan

It can enter the bloodstream during invasive fungal infection.

What does a positive BDG mean?

It means:

Invasive fungal infection is possible.

It does not mean:

"This patient has Candida."

CDC describes BDG as an adjunctive test with limited specificity for Candida. (CDC)

31. β-D-glucan — important limitation

BDG can be positive with multiple invasive fungal infections.

Therefore:

Positive BDG
    ↓
Invasive fungal infection possible
    ↓
Which fungus?
    ↓
Clinical context
+ cultures
+ imaging
+ other biomarkers
+ molecular tests

32. BDG and Mucorales

A very important comparison from your previous mycology work:

Mucorales generally do not produce a useful BDG signal.

Therefore:

Negative BDG does not exclude mucormycosis.

And:

Positive BDG pushes you toward Candida/Aspergillus/Pneumocystis and other BDG-producing fungi, depending on the clinical context.

33. β-D-glucan false positives

Potential causes include:

Hemodialysis-related exposures
Certain blood products
Some antimicrobial preparations
Intravenous products/materials
Severe bacterial infections in some circumstances
Other clinical/laboratory factors

Therefore:

Never interpret BDG in isolation.

34. Antifungal susceptibility testing — why?

Because Candida species are not pharmacologically identical.

Important examples:

C. krusei

→ intrinsically resistant to fluconazole

C. glabrata

→ azole susceptibility can be reduced/resistance can develop

C. parapsilosis

→ higher echinocandin MICs than many other Candida species

C. auris

→ multidrug resistance may occur

IDSA recommends azole susceptibility testing for bloodstream and other clinically relevant Candida isolates and consideration of echinocandin susceptibility testing in selected situations, including C. glabrata and C. parapsilosis. (Infectious Diseases Society of America)

35. AST methods

Common approaches include:

Broth microdilution

Reference method.

Commercial systems

May provide MICs.

Gradient diffusion

Useful in some laboratory settings.

Automated susceptibility platforms

Can be used where validated.

36. MIC ≠ automatically susceptible/resistant

You must interpret the MIC according to:

Species
Antifungal
Testing method
Current clinical breakpoint or epidemiological cutoff where appropriate

This is particularly important for uncommon Candida species.

37. Now: Candida auris

This deserves a separate mental category.

C. auris is not simply:

"another Candida species."

It is simultaneously a:

Clinical pathogen

Colonizer

Healthcare-associated transmission problem

Antimicrobial-resistance problem

Laboratory identification problem

CDC's current overview describes C. auris as a yeast capable of colonization and invasive disease, with high transmissibility in healthcare settings and frequent antifungal resistance. (CDC)

38. Why does Candida auris matter?

Because it can:

1. Cause invasive disease

Especially:

Candidemia
Wound infection
Other invasive infections

2. Colonize patients

Without symptoms.

3. Persist for prolonged periods

Colonization can continue long after clinical infection has resolved.

4. Spread efficiently in healthcare environments

5. Persist on surfaces

6. Be difficult to identify using some conventional systems

7. Be resistant to multiple antifungal classes

That combination is what makes C. auris so important. (CDC)

39. Colonization vs infection

This is perhaps the most important conceptual distinction.

Colonization

C. auris is detected:

On skin
In axilla/groin or other screening sites
Without evidence of active disease

The patient may have:

No symptoms.

But they can still transmit the organism.

Infection

There is clinical disease attributable to C. auris.

Examples:

Candidemia
Wound infection
Intra-abdominal infection
Other invasive disease

Critical principle

Colonization is not the same as infection.

Current CDC guidance explicitly states that only clinical infections should be treated; colonized patients should not receive antifungal therapy solely because screening is positive. (CDC)

40. Why colonization is dangerous

Because:

Colonized patient
       ↓
Organism persists on skin
       ↓
Contaminates environment/equipment
       ↓
Healthcare workers / equipment
       ↓
Other patients
       ↓
New colonization
       ↓
Invasive infection in susceptible patient

Therefore:

A colonized patient is an infection-control problem even when they are not a treatment problem.

41. Healthcare-associated transmission

C. auris can spread through:

Direct patient contact
Healthcare worker hands
Shared medical equipment
Contaminated surfaces
Patient-room environment

CDC notes that C. auris can persist on surfaces for prolonged periods and can contaminate high-touch surfaces and medical equipment. (CDC)

42. Why environmental persistence matters

Think of:

Bedrails
Bedside tables
Door handles
Blood pressure equipment
Thermometers
Monitoring equipment
Other shared devices

If the environment is not appropriately cleaned:

The hospital environment becomes part of the transmission cycle.

43. Infection-control response

Once C. auris is confirmed or strongly suspected:

Think immediately:

Patient + contacts + environment + laboratory + public health

Patient

Appropriate isolation/contact precautions according to institutional policy.

Equipment

Prefer:

Dedicated equipment

where feasible.

Environment

Thorough cleaning and disinfection.

Hand hygiene

Strict compliance.

Communication

Clearly document colonization/infection status during:

Transfer
Referral
Discharge

CDC's current infection-control guidance emphasizes environmental cleaning, hand hygiene, staff training and communication of C. auris status during transfers. (CDC)

44. Identification problem

This is a classic clinical microbiology trap.

A routine yeast isolate may be reported as:

Candida haemulonii complex
Candida famata
Rhodotorula
Other uncommon yeasts

depending on the identification platform and database.

CDC specifically warns that traditional biochemical systems can misidentify C. auris. (CDC)

Therefore:

An unusual Candida result in a high-risk healthcare patient should trigger scrutiny of the identification method.

45. How should C. auris be confirmed?

High-quality methods include:

MALDI-TOF MS

with an updated validated database

Molecular/sequencing methods

depending on laboratory capability.

CDC currently states that accurate identification requires mass spectrometry or sequencing/molecular approaches, depending on the testing context. (CDC)

46. C. auris — CHROMagar

On chromogenic media, C. auris may produce:

White
Pink
Sometimes red/purple colonies

The exact appearance varies.

Therefore:

Do not identify C. auris by colony colour alone.

CDC notes that colony colour can vary even on CHROMagar. (CDC)

47. C. auris — temperature clue

C. auris has notable thermotolerance.

It can grow at approximately:

40–42°C

This can be useful as a supplementary characteristic, but it is not sufficient for identification. (CDC)

48. C. auris — resistance

This is one of its defining clinical problems.

Resistance can occur to:

Azoles

Especially:

Fluconazole

Polyenes

Including:

Amphotericin B

Echinocandins

Resistance is particularly concerning because echinocandins are generally the initial treatment class for invasive C. auris infection.

Some isolates can become:

Pan-resistant

meaning resistance to all three major antifungal classes.

CDC reports increasing echinocandin-resistant and pan-resistant cases and recommends susceptibility testing for clinical C. auris isolates. (CDC)

49. Resistance is not uniform

Very important:

Do not memorize:

"C. auris is resistant to everything."

That is incorrect.

Instead:

C. auris has a high propensity for antifungal resistance, and resistance varies by isolate.

Therefore:

Species identification + AST

are critical.

50. C. auris — India-specific laboratory perspective

This is particularly relevant for you.

ICMR has a dedicated Candida auris advisory, and its current guideline repository continues to list that advisory along with the ICMR mycology laboratory SOPs. (ICMR)

More recently, the NCDC fungal AMR network reported that among Candida isolates from blood cultures submitted to its fungal national reference laboratory during 2024, C. auris accounted for 8% of characterized isolates in that dataset. The same dataset showed non-albicans Candida predominance, with C. tropicalis the largest group among the submitted isolates. This is surveillance-network data, not a prevalence estimate for all Indian hospitals. (NCDC)

That distinction matters when interpreting surveillance numbers.

51. Reporting considerations

For a clinical microbiologist, C. auris should trigger:

1. Laboratory notification

Do not bury it in a routine Candida report.

2. Infection-control notification

Because colonization itself has transmission implications.

3. Public-health notification according to applicable jurisdictional requirements

CDC recommends immediate communication with public-health authorities for suspected/confirmed cases in the U.S. (CDC)

In India, laboratories should follow their institutional/state/national surveillance and reporting pathways, including applicable NCDC/IDSP and public-health requirements; ICMR has specifically issued a C. auris advisory. (ICMR)

4. Transfer communication

The patient's C. auris colonization/infection status should accompany inter-facility transfer because the infection-control implications persist. (CDC)

52. What should the laboratory report say?

The exact wording should follow your laboratory's validated reporting policy, but conceptually a report should distinguish:

Clinical isolate

Candida auris isolated from blood — clinically significant; antifungal susceptibility testing recommended/performed.

versus

Screening isolate

Candida auris detected from screening specimen — colonization detected; correlate clinically.

Don't casually label a positive screening swab as:

"Candidiasis."

That confuses colonization with infection.

53. C. auris — laboratory algorithm

UNUSUAL YEAST ISOLATED
          ↓
High-risk healthcare patient?
          ↓
       YES
          ↓
Review identification method
          ↓
Could this be C. auris?
          ↓
 ┌────────┴────────┐
 ↓                 ↓
Validated        Uncertain/
ID available     suspicious ID
 ↓                 ↓
MALDI-TOF /       Refer isolate
molecular        to reference lab
 ↓                 ↓
 └────────┬────────┘
          ↓
      C. auris confirmed
          ↓
 ┌────────┴─────────────┐
 ↓                      ↓
Clinical isolate       Screening isolate
 ↓                      ↓
AST                     Colonization
 ↓                      ↓
Treatment decision      Infection-control
                        response
          ↓
Notify infection-control/public health
according to applicable requirements

54. Colonization screening

Screening is generally performed using:

Skin swabs

especially:

Axilla
Groin

Screening can identify patients who are asymptomatically colonized and therefore relevant to infection prevention. (CDC)

55. Screening vs clinical culture

This distinction is extremely important.

Situation	Interpretation
Axillary/groin screening swab positive	Colonization unless clinical evidence says otherwise
Blood culture positive	Candidemia/invasive infection
Wound culture positive	Requires clinical correlation
Urine positive	Colonization vs UTI must be assessed
Respiratory specimen positive	Usually colonization; clinical context essential

56. Candida from respiratory specimens

This is a classic microbiology trap.

Candida isolated from:

Sputum
Endotracheal aspirate
BAL

usually represents:

Colonization

rather than Candida pneumonia.

True Candida pneumonia is uncommon.

Therefore:

Do not diagnose Candida pneumonia simply because Candida grows from respiratory secretions.

This principle is explicitly recognized in the IDSA candidiasis guideline. (Infectious Diseases Society of America)

57. Blood vs urine vs respiratory specimen

This comparison is worth memorizing:

Specimen	Candida isolation means
Blood	Highly significant → candidemia
Urine	Colonization or infection; interpret clinically
Sputum/ET aspirate	Usually colonization
Oral swab	Often colonization
Vaginal specimen	Interpret with symptoms/signs
Sterile tissue/aspirate	Strong evidence of invasive disease when clinically appropriate

58. Candidemia — what does the microbiologist need to do?

When blood culture grows Candida:

Immediately:

1. Identify to species

2. Perform/recommend AST according to laboratory policy and clinical context

3. Alert the clinical team promptly

4. Consider catheter/device relevance

5. Consider metastatic complications

6. Follow blood culture clearance according to clinical management

Current CDC guidance notes that echinocandins are generally initial therapy for most adult candidemia, while species and susceptibility results guide subsequent treatment. (CDC)

59. The laboratory tests — what question does each answer?

This is one of the best ways to remember the entire chapter.

Test	Question it answers
KOH/Gram	Is there yeast/fungal morphology?
Germ tube	Could this be C. albicans/C. dubliniensis?
Chromogenic agar	Which Candida species is this likely to be?
MALDI-TOF	What species is this?
Automated ID	What species does the validated system identify?
Blood culture	Is Candida in the bloodstream?
β-D-glucan	Is invasive fungal infection plausible?
AST	Which antifungal agents are likely to be active?
Screening swab	Is the patient colonized with C. auris?

60. One major conceptual trap

Positive β-D-glucan

does NOT mean:

"Candida infection confirmed."

Positive Candida culture from urine

does NOT mean:

"Candida UTI confirmed."

Candida from sputum

does NOT mean:

"Candida pneumonia."

C. auris screening positive

does NOT mean:

"Invasive candidiasis."

Blood culture positive for Candida

is a very different situation.

61. 10 clinical microbiology cases

Case 1 — Thrush

HIV-positive patient develops removable white oral plaques.

KOH:

Budding yeast + pseudohyphae.

Diagnosis

Oropharyngeal candidiasis

Most likely:

C. albicans

Case 2 — Esophagus

Patient with oral thrush develops severe odynophagia.

Endoscopy:

White esophageal plaques.

Biopsy/brushings:

Candida forms.

Diagnosis

Candida esophagitis

Case 3 — Vaginal candidiasis

Woman with intense vulvovaginal pruritus.

KOH:

Budding yeast + pseudohyphae

Diagnosis

Vulvovaginal candidiasis

Most likely:

C. albicans

Case 4 — Candidemia

ICU patient with central line develops fever and sepsis.

Blood culture:

Budding yeast

MALDI-TOF:

C. glabrata

Interpretation

Candidemia due to C. glabrata

Species-level identification has therapeutic significance because reduced azole susceptibility/resistance can occur.

Case 5 — Neonatal candidemia

Premature neonate with central venous catheter develops candidemia.

Blood culture:

C. parapsilosis

Think:

Catheter + neonate + Candida = C. parapsilosis

Case 6 — Candiduria

Elderly catheterized patient has urine culture:

10⁵ CFU/mL Candida

No urinary symptoms.

Diagnosis?

Not automatically Candida UTI.

Most likely interpretation:

Candiduria/colonization, pending clinical context.

Case 7 — Candida in sputum

Ventilated ICU patient has:

Candida albicans isolated from endotracheal aspirate.

Does this prove Candida pneumonia?

No.

Usually represents:

Airway colonization

unless there is compelling evidence of true invasive pulmonary disease.

Case 8 — Hepatosplenic disease

Patient with acute leukemia develops persistent fever during neutrophil recovery.

Blood cultures repeatedly negative.

CT:

Multiple small liver and splenic lesions.

Think:

Chronic disseminated/hepatosplenic candidiasis

Negative blood culture does not exclude it.

Case 9 — Candida auris colonization

A patient transferred from another healthcare facility has a positive axilla/groin screening swab for C. auris.

No fever.

No clinical infection.

Diagnosis

C. auris colonization

What is needed?

Not antifungal treatment simply because of the positive screen.

Instead:

Infection-control response.

CDC specifically recommends infection-control measures for both colonized and infected patients. (CDC)

Case 10 — C. auris identification trap

An ICU patient's blood culture grows an unusual yeast.

An older biochemical system reports:

Candida haemulonii complex

The patient has been hospitalized for several weeks and has a central line.

What should you do?

Think:

Could this be Candida auris?

→ Review identification platform/database→ Refer/confirm using appropriate modern identification→ Alert infection prevention if suspected→ Perform susceptibility testing on clinical isolate→ Follow applicable public-health reporting procedures

CDC specifically identifies C. haemulonii complex isolates as a group warranting further consideration in certain identification systems. (CDC)

62. C. auris — the five-question memory system

When you hear C. auris, immediately ask:

1. Could this be misidentified?

YES

↓

2. Could the patient simply be colonized?

YES

↓

3. Could it spread in the hospital?

YES

↓

4. Could it be multidrug-resistant?

YES

↓

5. Does infection-control need to know?

YES

That's the entire organism in five questions.

63. C. auris vs ordinary Candida

Feature	Typical Candida	C. auris
Colonization	Common	Important and persistent
Invasive disease	Yes	Yes
Healthcare transmission	Possible	Major concern
Environmental persistence	Variable	Marked
Identification	Usually straightforward	Can be difficult
Resistance	Species-dependent	Often resistant to ≥1 class
Multidrug resistance	Variable	Important problem
Screening	Usually not routine	Important in appropriate settings
Infection-control impact	Standard Candida precautions	Enhanced response required

64. Candida I + Candida II — one master table

Species	Morphology	Key lab clue	Major clinical clue	Resistance pearl
C. albicans	Yeast + pseudohyphae + true hyphae	Germ tube +	Mucosal + invasive	Usually susceptible to many agents, but resistance can occur
C. glabrata	Small yeast; little/no pseudohyphae	Germ tube –	Invasive/urinary	Azole resistance/reduced susceptibility
C. tropicalis	Abundant pseudohyphae/hyphae	Chromogenic/ID methods	Neutropenia	Resistance varies
C. parapsilosis	Yeast + pseudohyphae	ID/CHROMagar/MALDI	Catheter/neonate	Higher echinocandin MICs
C. krusei	Elongated yeast/pseudohyphae	Rough colony	Invasive disease	Intrinsic fluconazole resistance
C. auris	Yeast, usually no prominent hyphae	Modern ID required	Healthcare-associated	Multidrug resistance possible

65. The ultimate Candida diagnostic algorithm

PATIENT WITH POSSIBLE CANDIDA DISEASE
                │
                ↓
         WHAT IS THE SITE?
                │
 ┌──────────────┼──────────────────┐
 ↓              ↓                  ↓
Mucosal       Urinary          Blood/sterile site
 ↓              ↓                  ↓
Clinical      Colonization      HIGH SIGNIFICANCE
+ microscopy  vs infection          ↓
                                Species ID
                                    ↓
                              MALDI/automated/
                              molecular methods
                                    ↓
                                AST
                                    ↓
                       Assess invasive complications
                                    ↓
                            Clinical management

66. And the C. auris branch

UNUSUAL YEAST
     ↓
High-risk healthcare setting?
     ↓
    YES
     ↓
Could it be C. auris?
     ↓
Review identification method
     ↓
Confirm with validated modern method
     ↓
        C. auris
          │
    ┌─────┴─────┐
    ↓           ↓
COLONIZATION  INFECTION
    ↓           ↓
IPC response   Treat clinically
    ↓           ↓
Screening/     AST
contact        ↓
management     IPC
    └─────┬─────┘
          ↓
Public-health / institutional
reporting as applicable

67. The final 20 facts you should know cold

Candida is a normal colonizer of multiple body sites.
Colonization ≠ infection.
C. albicans is classically germ-tube positive.
C. dubliniensis can also be germ-tube positive.
C. albicans can form true hyphae, pseudohyphae and chlamydoconidia.
C. glabrata is predominantly a small budding yeast with little filamentation.
C. tropicalis commonly produces abundant pseudohyphal/hyphal forms.
C. parapsilosis is strongly associated with catheters and neonates.
C. parapsilosis has relatively higher echinocandin MICs.
C. krusei is intrinsically resistant to fluconazole.
Candida in blood = candidemia, not simple colonization.
Negative blood cultures do not exclude deep-seated candidiasis.
Candida in respiratory secretions usually represents colonization.
Candiduria does not automatically mean UTI.
Hepatosplenic candidiasis occurs particularly in patients with hematological malignancy/neutropenia.
β-D-glucan is adjunctive, not Candida-specific.
MALDI-TOF provides rapid species identification when the database supports the organism.
C. auris can be colonization or invasive infection.
C. auris is a major healthcare-associated transmission and resistance problem.
A confirmed C. auris result should trigger laboratory + clinical + infection-control + appropriate public-health communication, not merely an antifungal prescription.

The single most important clinical-microbiology principle

Never interpret a Candida result without asking: “From where was it isolated, in what patient, and does that site represent colonization or invasive disease?”

That one question will prevent a huge number of Candida diagnostic errors.